
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc. reported third-quarter revenues of $136.1 million, exceeding consensus estimates and demonstrating a robust year-over-year growth of 69% alongside a quarterly increase of 14%, supported by approximately 209,000 prescriptions. The company's improved payer coverage, now at 85%, enhances its market accessibility, contributing to revenue potential as they also plan to launch a pediatric ADHD study and anticipate key data releases for other indications in 2026. Furthermore, Axsome's ongoing product innovations and anticipated operational leverage indicate a trajectory toward achieving positive cash flow by 2026, enhancing its investment appeal.
Bears say
Axsome Therapeutics Inc. is projected to experience modestly declining revenues, with the full-year 2025 forecast set at $628.3 million compared to $630.5 million previously. The company faces significant risks, including potential setbacks in clinical trials for key products like AXS-05 and AXS-12, as well as uncertainties regarding market access for AUVELITY and competition impacting commercial success. Additionally, regulatory approval delays and long-term dilution risks further exacerbate concerns about its financial stability and growth prospects in the highly competitive CNS therapeutics market.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares